General Electric
http://www.ge.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From General Electric
Finance Watch: Stark Contrast As Big FOPOs Reach Market, Other Firms Cut Costs
Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.
Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing
The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.
Ipsen In Pole Position For Rare Liver Disease
The FDA is set to make a decision on elafibranor for primary biliary cholangitis by June next year, which could give Ipsen a head start over CymaBay's seladelpar.
Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar
Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis.
Company Information
- Industry
- Diversified
- Medical Devices
- Other Names / Subsidiaries
-
- Amersham
- Clarient Inc.
- Asymptote Limited
- GE Healthcare
- GE Medical Systems LLC
- Monica Healthcare
- Novia Strategies
- Vital Signs.
- Xcellerex
- U-Systems
- Zionexa SAS
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice